Laboratory and Diagnostic Evaluation for Systemic Inflammation and Diffuse Body Pain

Initial Core Laboratory Panel

ESR and CRP should be obtained at baseline in every patient with suspected inflammatory disease; CRP is slightly more sensitive and specific for acute inflammation. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1
A complete blood count is recommended to identify anemia, leukocytosis, or thrombocytosis that may accompany systemic inflammation. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 2
A comprehensive metabolic panel—including liver enzymes, creatinine, glucose, and urate—should be ordered to detect organ involvement and rule out metabolic mimics. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1
Urinalysis is advised to screen for proteinuria (renal involvement) or myoglobinuria (possible rhabdomyolysis). – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4

Creatine kinase (CK) is the single most sensitive laboratory marker for muscle inflammation and is required to differentiate myositis from pain‑only syndromes. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Cardiac troponin must be measured whenever myositis is suspected because concurrent myocarditis carries a markedly higher mortality. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Aldolase, lactate dehydrogenase (LDH), AST, and ALT provide adjunctive evidence of muscle inflammation and help separate myositis from primary hepatic disease. – Praxis Medical Insights (2026) 3
Myositis‑specific autoantibodies (e.g., anti‑Jo‑1, anti‑Mi‑2, anti‑SRP, anti‑TIF1γ, anti‑NXP2) should be ordered when CK is elevated or objective weakness is documented. – Praxis Medical Insights (2026) 3
Anti‑acetylcholine‑receptor and anti‑striational antibodies are indicated if a myasthenia gravis overlap is suspected, given the high‑mortality myositis‑myasthenia‑myocarditis triad. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4

Rheumatoid factor (RF) and anti‑citrullinated protein antibodies (ACPA) are strongly predictive of rheumatoid arthritis diagnosis and progression; negative results do not rule out RA. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1
Antinuclear antibody (ANA) testing should be considered in the work‑up of suspected connective‑tissue disease or systemic inflammatory disorders. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 2
HLA‑B27 testing is indicated when clinical features suggest reactive arthritis or axial spondyloarthropathy. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Extractable nuclear antigen (ENA) panel and anti‑double‑stranded DNA antibodies are recommended when systemic lupus erythematosus or mixed connective‑tissue disease is in the differential. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1

Baseline plain radiographs of symptomatic joints (hands, wrists, feet) are advised; erosions on imaging predict development and persistence of rheumatoid arthritis. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 2
Chest radiography should be performed to exclude pulmonary involvement, malignancy, or sarcoidosis. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1
MRI of proximal muscles is recommended when myositis is suspected and CK is elevated, to guide biopsy site selection and monitor therapeutic response. – Praxis Medical Insights (2026) 3

Obtain ESR, CRP, CBC, comprehensive metabolic panel, and urinalysis. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1
If ESR > 50 mm/hr, add RF and ACPA testing. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 2
Consider plain radiographs of the symptomatic joints. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 2

Perform all investigations listed for mild disease. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1
Add a full autoimmune panel (ANA, RF, ACPA, anti‑ENA). – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 2
Obtain joint imaging (ultrasound or MRI) if synovitis is evident or symptoms persist despite initial therapy. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Refer to rheumatology within 1–2 weeks for specialist evaluation. – Praxis Medical Insights (2026) 3

Immediately order CK, cardiac troponin, aldolase, LDH, AST, ALT, ESR, CRP, CBC, comprehensive metabolic panel, and urinalysis. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Include myositis‑specific antibodies and anti‑acetylcholine‑receptor antibodies. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4 (myositis‑specific antibodies also from Praxis 3)
Perform ECG and consider echocardiography or cardiac MRI if troponin is elevated. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Arrange same‑day specialist referral and consider hospital admission for urgent management. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4

Never omit cardiac troponin testing when myositis is suspected; concurrent myocarditis markedly increases mortality. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
A normal CK does not exclude inflammatory disease; conditions such as polymyalgia rheumatica can present with severe pain and elevated ESR/CRP despite normal CK. – Praxis Medical Insights (2026) 3
Distinguish pain‑limited movement from true objective weakness by formally testing proximal muscle strength (e.g., shoulder abduction, hip flexion). – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Screen for medication‑induced myopathy (e.g., statins, immune‑checkpoint inhibitors) as these agents can precipitate severe, potentially fatal myositis even months after exposure. – American Society of Clinical Oncology (Journal of Clinical Oncology 2021) 4
Negative RF and ACPA do not rule out progression to rheumatoid arthritis; ongoing clinical follow‑up and repeat serology may be required. – American College of Rheumatology (Annals of the Rheumatic Diseases 2011) 1